Gastrointestinal Stromal Tumor
📧 Sign up to get email alerts when something new happens for Gastrointestinal Stromal Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Caphosol in Oral Mucositis Due to Targeted Therapy [Phase 3]
A Phase 3 trial evaluating Caphosol for oral mucositis caused by targeted cancer therapies has completed.
-
CLINICAL_TRIALS trial_result · 2017-11-01Clinical Trial Update: A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma [Phase 2]
Phase II trial of nivolumab plus ipilimumab in non-resectable soft tissue and bone sarcomas, with exploration across several sarcoma subtype…
-
FDA approval · 2017-09-29FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental NDA for GLEEVEC (imatinib mesylate) filed by Novartis Pharmaceuticals Corporation, resulting in changes to the p…
-
CLINICAL_TRIALS trial_result · 2017-09-14Clinical Trial Update: Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor [Phase 3]
Phase 3 trial evaluating imatinib mesylate with or without bevacizumab in metastatic or unresectable gastrointestinal stromal tumor was term…
-
CLINICAL_TRIALS trial_result · 2017-08-29Clinical Trial Update: Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Clinical trial registry update indicating completion of NCT01770405 evaluating needle-based confocal laser endomicroscopy (nCLE) for masses …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-22Clinical Trial Update: Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients
This update summarizes treatment response evaluation in patients with Gastrointestinal Stromal Tumor (GIST) from a completed clinical trial …
-
FDA approval · 2017-06-21FDA Approved: IMATINIB MESYLATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's original application for imatinib mesylate tablets, a generic version of Gleevec, for the same indications as the refer…
-
CLINICAL_TRIALS trial_result · 2017-05-31Clinical Trial Update: Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) [Phase 2]
A completed Phase 2 study evaluating two years of adjuvant imatinib therapy for gastrointestinal stromal tumors, reporting safety and effica…
-
CLINICAL_TRIALS research · 2017-05-31Clinical Trial Update: POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST [Phase 2]
A Phase 2 trial (POETIG) is evaluating ponatinib for imatinib-resistant gastrointestinal stromal tumors with KIT mutations, including exon 1…
-
CLINICAL_TRIALS research · 2017-05-16Clinical Trial Update: Long Outcome of Endoscopic Submucosal Dissection for Small Gastrointestinal Stromal Tumors (<2cm) [NA]
The document provides an update on long-term outcomes of endoscopic submucosal dissection for small gastrointestinal stromal tumors (<2 cm).
-
FDA label_change · 2017-04-27FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA page documents Bayer's supplemental application for Stivarga (regorafenib), indicating a label change is being sought.
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) [Phase 2]
Phase 2 trial of pazopanib in patients with imatinib-refractory or intolerant gastrointestinal stromal tumors; the study was terminated and …
-
CLINICAL_TRIALS trial_result · 2017-03-15Clinical Trial Update: Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) [Phase 2]
Phase 2 trial evaluating nilotinib alone or with imatinib for advanced gastrointestinal stromal tumor; the study was terminated but results …
-
CLINICAL_TRIALS trial_result · 2017-02-28Clinical Trial Update: Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) [Phase 2]
Phase 2 clinical trial evaluating Nilotinib in patients with advanced gastrointestinal stromal tumor has completed.
-
CLINICAL_TRIALS trial_result · 2017-02-14Clinical Trial Update: Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)
This entry provides an update on a clinical trial evaluating circulating cell-free tumor DNA in the plasma of patients with Gastrointestinal…
-
CLINICAL_TRIALS trial_result · 2017-01-19Clinical Trial Update: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors [Phase 2]
Phase 2 trial of linsitinib in patients with gastrointestinal stromal tumors (and related conditions) has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-01-16Clinical Trial Update: A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors [Phase 2]
A Phase 2 study of olaratumab (IMC-3G3) in previously treated patients with unresectable and/or metastatic gastrointestinal stromal tumors w…
-
CLINICAL_TRIALS trial_result · 2017-01-10Clinical Trial Update: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic [Phase 1]
A Phase 1 study evaluating the combination of dasatinib and ipilimumab in patients with gastrointestinal stromal tumor or unresectable/metas…
-
CLINICAL_TRIALS trial_result · 2017-01-09Clinical Trial Update: A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen [Phase 1]
Phase 1 study of a mixed bacteria vaccine (MBV) targeting NY-ESO-1 tissue expression in various tumors; completed with posted results.
-
CLINICAL_TRIALS trial_result · 2016-11-18Clinical Trial Update: Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) [Phase 2]
Phase II neoadjuvant trial evaluating imatinib mesylate for patients with gastrointestinal stromal tumors has completed.
-
CLINICAL_TRIALS research · 2016-10-13Clinical Trial Update: Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor
This clinical trial update examines serum Dickkopf-4 as a biomarker for diagnosing and guiding treatment of gastrointestinal stromal tumor (…
-
CLINICAL_TRIALS trial_result · 2016-10-04Clinical Trial Update: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor [Phase 2]
Phase 2 trial of the Hsp90 inhibitor AUY922 for refractory gastrointestinal stromal tumors has completed and results have been posted.
-
FDA approval · 2016-08-25FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2016-08-24Clinical Trial Update: Sarcopenia in Patients With Gastrointestinal Stromal Tumours
A clinical trial evaluating sarcopenia in patients with gastrointestinal stromal tumors has completed.
-
FDA approval · 2016-08-17FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for imatinib mesylate, a generic version of the cancer drug, to update its approval status.